中國能建(601868.SH):中國能建集團加快增持1.43億元股份
格隆匯4月8日丨中國能建(601868.SH)公佈,加快了增持實施進度,於2025年4月1日至4月8日期間,中國能建集團增持本公司A股6549.56萬股,共計增持金額1.43億元(不含手續費)。自2024年10月15日至本公告日,中國能建集團通過上海證券交易所證券交易系統以集中競價方式累計增持本公司A股136,680,556股,佔本公司總股本的0.33%,累計增持金額300,007,368元(不含手續費),超過本次增持計劃金額下限。中國能建集團將持續關注資本市場發展態勢和本公司股票價格走勢,適時開展增持工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.